Skip to main content
. 2020 Oct 19;10(4):179. doi: 10.3390/jpm10040179

Figure 1.

Figure 1

Effects of Nivolumab and Ipilimumab mAbs on SK-BR-3 tumor cells co-cultured with hPBMCs as well as on human cardiomyocytes co-cultured with hPBMCs. (A) Cell viability assay on SKBR-3 tumor cells, treated with Nivolumab or Ipilimumab mAb for 24 h, in the presence of hPBMCs. Untreated cells (white bars) or cells treated with an unrelated control Immunoglobulin G (IgG) (grey bars) were used as negative controls. Cells were counted by Trypan blue after the removal of lymphocytes. (B) LDH assay on the supernatant of co-cultures treated as indicated. Cell lysis was measured as described in the Materials and Methods section. (C) Representative images of SK-BR-3 tumor cells co-cultured with lymphocytes and treated as indicated. (D) Cell viability assay on HFC cells, treated with Nivolumab or Ipilimumab mAb for 24 h, in the presence of lymphocytes. Untreated cells (white bars) or cells treated with an unrelated control IgG (grey bars) were used as negative controls. (E) LDH assay on the supernatant of co-cultures treated as indicated. Cell lysis was measured as described in the Materials and Methods section. (F) Representative images of HFC treated in the presence of lymphocytes. Error bars depict means ± SD. p-values for the indicated compounds relative to untreated cells are: * p < 0.05; ** p < 0.01.